Recursion Pharmaceuticals Inc (NASDAQ:RXRX) — Market Cap & Net Worth
Market Cap & Net Worth: Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a market capitalization of $1.73 Billion ($1.73 Billion) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6819 globally and #2057 in its home market, demonstrating a -0.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Recursion Pharmaceuticals Inc's stock price $3.29 by its total outstanding shares 524677865 (524.68 Million). Review Recursion Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
Recursion Pharmaceuticals Inc Market Cap History: 2021 to 2026
Recursion Pharmaceuticals Inc's market capitalization history from 2021 to 2026. Data shows change from $8.99 Billion to $1.73 Billion (-35.34% CAGR).
Index Memberships
Recursion Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.07% | #179 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.00% | #740 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.10% | #113 of 263 |
Weight: Recursion Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Recursion Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Recursion Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
28.73x
Recursion Pharmaceuticals Inc's market cap is 28.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $8.99 Billion | $10.00 Million | -$178.07 Million | 898.77x | N/A |
| 2022 | $4.05 Billion | $39.68 Million | -$239.42 Million | 101.94x | N/A |
| 2023 | $5.17 Billion | $43.88 Million | -$328.07 Million | 117.91x | N/A |
| 2024 | $3.55 Billion | $58.84 Million | -$463.66 Million | 60.28x | N/A |
| 2025 | $2.15 Billion | $74.68 Million | -$644.76 Million | 28.73x | N/A |
Competitor Companies of RXRX by Market Capitalization
Companies near Recursion Pharmaceuticals Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Recursion Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Recursion Pharmaceuticals Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Recursion Pharmaceuticals Inc's market cap moved from $8.99 Billion to $ 1.73 Billion, with a yearly change of -35.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.73 Billion | -19.56% |
| 2025 | $2.15 Billion | -39.50% |
| 2024 | $3.55 Billion | -31.44% |
| 2023 | $5.17 Billion | +27.89% |
| 2022 | $4.05 Billion | -54.99% |
| 2021 | $8.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Recursion Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.73 Billion USD |
| MoneyControl | $1.73 Billion USD |
| MarketWatch | $1.73 Billion USD |
| marketcap.company | $1.73 Billion USD |
| Reuters | $1.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more